Tirzepatide vs Semaglutide

Overview

This comparison separates Tirzepatide and Semaglutide for reference—not product selection.

Tirzepatide: Dual GIP and GLP-1 receptor agonist, approved for type 2 diabetes and weight management.

Semaglutide: GLP-1 receptor agonist approved for type 2 diabetes and weight management; the most studied compound in its class.

Differences

• Both appear in Metabolic & GLP-1 research literature, but mechanistic framing differs.
• The useful distinction is research question and receptor context—not relative potency or practical ranking.

Mechanism

Tirzepatide: Tirzepatide acts on two hormone pathways at once — the GIP and GLP-1 receptors. Both hormones are released by the gut after a meal and both increase insulin rel…

Semaglutide: Semaglutide activates the GLP-1 receptor. In plain terms it extends and amplifies the signal your body normally sends after a meal: the stomach empties more slo…

Pharmacology

Tirzepatide: Pharmacokinetic detail should be read from primary literature.

Semaglutide: Pharmacokinetic detail should be read from primary literature.

Research

Tirzepatide: Metabolic & GLP-1 research: Clinical trials demonstrate 15-22% body weight reduction in non-diabetic obese individuals, superior to existing weight loss medications.

Semaglutide: Metabolic & GLP-1 research: FDA-approved for chronic weight management with average 15-20% body weight loss in clinical trials.

Summary

Distinction

• AXIOM does not provide dosing, administration, or protocol guidance.
• Catalogue links appear only where AXIOM lists a research-use product.
• Reference-only compounds remain comparison terms without implying availability.

References

• pubmed.ncbi.nlm.nih.gov/41406444/
• pubmed.ncbi.nlm.nih.gov/38912654/
• pubmed.ncbi.nlm.nih.gov/37385275/
• pubmed.ncbi.nlm.nih.gov/39536238/
• pubmed.ncbi.nlm.nih.gov/35658024/
• pubmed.ncbi.nlm.nih.gov/40353578/
• pubmed.ncbi.nlm.nih.gov/34170647/
• pubmed.ncbi.nlm.nih.gov/39555826/

Questions